Work with us
Contact us
If you think you have what it takes to help build a pharma-biotech company and accelerate value, please contact us. We are looking forward to receiving your full resume with areas of interest. All resumes will be treated in the strictest confidence.
Please submit your letter to: contact@abilitypharma.com
LATEST NEWS
05.10.2017
News
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017
News
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017
News
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
15.12.2016
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016
News
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016
News
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015
News
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014
News
Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
